Rapid drug susceptibility testing with a molecular beacon assay is associated with earlier diagnosis and treatment of multidrug-resistant tuberculosis in California

To assess the clinical impact of a molecular beacon (MB) assay that detects multidrug-resistant tuberculosis (MDR TB), we retrospectively reviewed records of 127 MDR TB patients with and without MB testing between 2004 and 2007. Use of the MB assay reduced the time to detection and treatment of MDR...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical microbiology Vol. 48; no. 10; p. 3779
Main Authors: Banerjee, Ritu, Allen, Jennifer, Lin, S-Y Grace, Westenhouse, Janice, Desmond, Ed, Schecter, Gisela F, Scott, Cheryl, Raftery, Ann, Mase, Sundari, Watt, James P, Flood, Jennifer
Format: Journal Article
Language:English
Published: United States 01.10.2010
Subjects:
Adult
Antitubercular Agents - pharmacology
Antitubercular Agents - therapeutic use
California
Early Diagnosis
Female
Humans
Male
Microbial Sensitivity Tests - methods
Middle Aged
Molecular Diagnostic Techniques - methods
Mycobacterium tuberculosis - drug effects
Mycobacterium tuberculosis - genetics
Mycobacterium tuberculosis - isolation & purification
Retrospective Studies
Time Factors
Tuberculosis, Multidrug-Resistant - diagnosis
Tuberculosis, Multidrug-Resistant - microbiology
California
ISSN:1098-660X, 1098-660X
Online Access:Get more information
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To assess the clinical impact of a molecular beacon (MB) assay that detects multidrug-resistant tuberculosis (MDR TB), we retrospectively reviewed records of 127 MDR TB patients with and without MB testing between 2004 and 2007. Use of the MB assay reduced the time to detection and treatment of MDR TB.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Undefined-1
ObjectType-Feature-3
content type line 23
ISSN:1098-660X
1098-660X
DOI:10.1128/JCM.01236-10